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The annual incidence of acute kidney injury (AKI) has been increasing as the population ages. Despite advances in
critical care and dialysis technology, the mortality remains unacceptably high in patients with AKI during the past
few decades. Renal replacement therapy (RRT) is performed to treat patients with severe AKI and multiple organ
failures, as well as to remove fluid in patients with fluid overload including those with acute heart failure and lung
edema in the intensive care unit (ICU). The mortality in patients with AKI requiring RRT is higher than 50 %. RRT
strategies in patients with AKI depend on various conditions. However, there is little consensus on when to start
and stop RRT, its optimal dose, and the choice of different RRT modalities (intermittent versus (vs.) continuous) in
patients with AKI. Patients with AKI in the ICU are preferentially treated with continuous rather than intermittent
RRT (IRRT), usually because of hemodynamic stability and steady of solute clearance. At present, the type and dose
of RRT are dependent on the experience of the attending clinicians, including intensivists and nephrologists.
Keywords: Acute kidney injury, Renal replacement therapy, Continuous renal replacement therapy, Intermittent
renal replacement therapy, Dose of renal replacement therapy, Modality of renal replacement therapyBackground
Acute kidney injury (AKI) is defined as a rapid decline
in glomerular filtration rate occurring over a period of
minutes to days, with retention of blood urea nitrogen
and serum creatinine (SCr). AKI is one of the most com-
mon and serious complications of critically ill patients in
intensive care unit (ICU). Approximately 4 % of ICU pa-
tients develop AKI requiring renal replacement therapy
(RRT) [1]. As no specific pharmacologic therapy is ef-
fective in AKI patients, their care is limited to supportive
management in which RRT plays a central role. Despite
advances in the understanding and management of AKI
including introduction of RRT, mortality in ICU patients
with AKI remains largely unimproved and unacceptably
high. Moreover, mortality in ICU patients with AKI se-
vere enough to require RRT has been reported to be as
high as 80 % [2, 3]. However, several issues regarding
RRT remain to be solved in patients with AKI (Table 1).
In particular, no consensus has been reached on the tim-
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hemodialysis (HD)), and type of dialysis membranes for
AKI. This review will discuss RRT for AKI in critically ill
patients.Review
Timing of initiation and discontinuation of RRT in
critically ill patients with AKI
Critically ill patients with AKI often require RRT, but
there is no consensus to guide clinicians on the timing
of initiation of RRT. The traditional indications for RRT
in critically ill patients with AKI include (1) volume over-
load resistant to diuretic agents, (2) sudden hyperkalemia,
(3) severe metabolic acidosis, and (4) uremic manifesta-
tions, including encephalopathy, pericarditis, and convul-
sion. Several studies have examined the timing of RRT
initiation in AKI patients in the ICU. It is unclear whether
the early initiation of RRT improves survival and renal re-
covery rates [4–9]. These studies, however, differ in their
definition of early and late initiation. In most studies, the
timing of RRT was assessed using conventional serum
biomarkers (e.g., serum urea and SCr levels), urine volume,
and the time from ICU admission to the start of RRT.distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 The controversial issues regarding RRT in AKI
1. Timing of initiation and discontinuation of RRT
2. RRT modality: CRRT vs. IRRT vs. SLED
3. Intensity (dose) of RRT
4. Dialysis membrane
5. Anticoagulation
6. RRT mode: HDF vs. HF vs. HD
RRT renal replacement therapy, AKI acute kidney injury, CRRT continuous renal
replacement therapy, IRRT intermittent renal replacement therapy, SLED
sustained low efficiency dialysis, HDF hemodiafiltration, HF hemofiltration,
HD hemodialysis
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evaluated whether the early initiation of RRT improved
mortality in patients with AKI [4, 5, 9]. In one study, Bour-
man et al. randomized 106 critically ill patients with AKI
into three groups, 35 were treated with early high-volume
HF (HVHF), 35 with early low-volume HF, and 36 with late
low-volume HF [4]. Early initiation of RRT was defined as
within 12 h of oliguria (urine output <30 mL/h for 6 h, or
creatinine clearance <20 mL/min), whereas late initiation
was defined as patient fulfillment of the conventional cri-
teria for RRT. Compared with late initiation, early initiation
of RRT did not improve mortality and dialysis dependence.
A second study, in Japan, evaluated whether early initiation
of RRT affected survival in 28 patients who developed
AKI after cardiac surgery [5]. Patients were randomized
to an early-start group, receiving RRT when urine volume
was <30 mL/h for 3 h, or conventional-start group who
waited to receive RRT until urine volume was <20 mL/h
for 2 h. Early RRT significantly improved patient survival
(p < 0.01), indicating that the timing of RRT initiation
in post-cardiac surgery patients with AKI should be de-
termined by urine volume not by SCr levels. In the
HEROICS trial, 224 patients with severe shock requir-
ing high-dose catecholamines following cardiac surgery
were randomized to early HVHF (80 mL/kg/h) for 48 h
followed by standard-volume continuous veno-venous
hemodiafiltration (CVVHDF) (n = 112) or to standard care
with delayed CVVHDF (n = 112) [9]. Patients in the latter
group received CVVHDF when SCr was >354 μmol/L
(>4 mg/dL) or had increased threefold from preoperative
levels; when urine output was <0.3 mL/kg/h for 24 h;
when urea was >36 mmol/L; or when they experienced
life-threatening hyperkalemia. The 30-day mortality was
36 % (40/112) in both groups (p = 1.00), and there were
also no significant differences in 60- and 90-day mortality.
Several observational studies have assessed the rela-
tionships between the timing of RRT and mortality and
renal recovery in critically ill patients with AKI requiring
RRT [6–8]. The largest prospective cohort study, involv-
ing patients at 54 ICUs in 23 countries, showed that the
timing of RRT influenced outcomes in critically illpatients with severe AKI [7]. In this study, the timing of
RRT initiation was stratified as early or late based on the
median SCr and serum urea levels. No differences in
mortality were observed between the early and late groups
stratified by serum urea levels. When the timing of RRT
was stratified by SCr levels, however, late RRT was as-
sociated with lower mortality than the early RRT. When
the timing of RRT was defined by the median time from
ICU admission to start of RRT, the crude mortality was
higher for late than early RRT (72.8 versus (vs.) 58.9 %,
p < 0.001).
A systematic review and meta-analysis showed that
early initiation of RRT in critically ill patients with AKI
may have a beneficial impact on survival compared with
late initiation [10]. However, this conclusion was based
on only two RCTs, with significant heterogeneity [4, 5].
These findings stress the need for further well-designed
RCTs assessing the effects of RRT timing on patient
survival.
On the other hand, no consensus has been reached on
the timing of discontinuation of RRT for AKI. As no RCTs
to date have evaluated the timing of discontinuation, the
factors determining the decision to stop RRT and the ef-
fects of the timing of discontinuation on patient outcomes
and recovery of renal function remain unclear. Only three
observational studies have investigated the discontinuation
of RRT in critically ill patients with AKI. Uchino et al. ex-
amined 529 patients who survived initial therapy among
1006 patients treated with continuous renal replacement
therapy (CRRT) [11]. They classified 313 AKI patients
weaned successfully from CRRT for at least 7 days as the
success group and 216 AKI patients needed repeat CRRT
within 7 days of discontinuation as the repeat-RRT group.
Patients in the success group had lower ICU and hospital
mortality compared with repeat-RRT group (p < 0.0001),
and those in the success group had lower SCr, urea, and
higher urine output at the discontinuation of CRRT. Multi-
variate logistic regression analysis showed that urine out-
put (odds ratio (OR), 1.078 per 100 mL/day) was the most
significant predictor of successful discontinuation of
CRRT. Wu et al. showed risk factors for early redialysis
in 94 patients with AKI who were weaned from RRT
after major surgery [12]. The independent predictors for
resuming dialysis within 30 days were (1) longer duration
of dialysis, (2) higher Sequential Organ Failure Assessment
(SOFA) score, (3) oliguria (urine output <100 mL/8 h, and
(4) age over 65 years. Kawarazaki et al. examined the
predictive factors of early kidney recovery (within 48 h)
after CRRT initiation in AKI patients in a multicenter
retrospective observational study of 14 Japanese ICUs.
In multivariable regression analysis, urine output (mL/h),
duration between ICU admission and CRRT initiation
(days), and the SOFA score were related to early kidney
recovery (OR 1.02, 0.65, 0.87; 95 % confidence interval
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0.007; respectively) [13].
0ptimal dose of RRT for AKI
Until now, the optimal dose of RRT for critically ill
patients with AKI remains unclear. Whether high dose of
RRT for AKI leads to the improvement of survival and
renal recovery remains controversial. In the first study
conducted by Ronco et al. evaluating the intensity of
CRRT, 425 critically ill patients with AKI at a single center
in Italy who were treated with continuous veno-venous
hemofiltration (CVVHF) were randomized to three
groups differing in filtration rate (20, 35, or 45 mL/kg/h)
[14]. The survival at 15 days after discontinuation of
CRRT was significantly lower in the lowest dose (41 %)
than in the intermediate (57 %, p = 0.007) and highest
(58 %, p = 0.0013) dose groups but did not differ in the
latter two groups. These findings suggest that a filtra-
tion rate ≥35 mL/kg/h was recommended for critically
ill patients with AKI requiring CRRT. Since then, rate at
35 mL/kg/h has come to be known as Roco dose widely
all over the world. Three subsequent RCTs evaluated the
optimal dose of CRRT for AKI [4, 15, 16]. However, all
three had small numbers of patients, making them in-
sufficiently powerful to show the effect of high-dose
CRRT on survival. One single-center study compared
CVVHF (mean prescribed filtration of 25 ± 5 mL/kg/h)
with CVVHDF (mean prescribed filtration of 24 ±
6 mL/kg/h +mean prescribed dialysis dose of 18 ±
5 mL/kg/h) in 206 patients with AKI [15]. This study
showed that the patient survival was significantly higher
in patients who received CVVHDF than CVVHF, both at
28 days (59 vs. 39 %, p = 0.03) and 90 days (59 vs. 34 %
p = 0.0005). In contrast, the other two studies failed to
show that increased CRRT dose improved survival in
patients with AKI [4, 16].
Moreover, in 2008 and 2009, two major multicenter
RCTs evaluating the impact of RRT dose on patient sur-
vival were conducted in the USA and in Australia and
New Zealand [17, 18]. These two trials were the first to
provide high-quality evidence guiding the prescribed
dose of CRRT in patients with severe AKI. The Veterans
Affairs/National Institutes of Health Acute Renal Failure
Trial Network (ATN) study randomly assigned critically
ill patients with AKI requiring RRT to intensive therapy
(n = 563) or less intensive therapy (n = 561) [17]. In the
intensive therapy group, pre-dilution CVVHDF was pre-
scribed to provide a total effluent flow rate of 35 mL/kg/h,
along with intermittent HD (IHD) and sustained low-
efficiency dialysis (SLED) six times per week. In the less
intensive therapy group, pre-dilution CVVHDF was pre-
scribed to provide a total effluent flow rate of 20 mL/kg/h,
as well as IHD and SLED three times per week. The pri-
mary endpoint was death from any cause by 60 days, andthe secondary endpoint included in-hospital death and
renal recovery. Of the patients in the intensive and less
intensive therapy groups, 302 (53.6 %) and 289 (51.5 %),
respectively, died within 60 days (OR 1.09, 95 % CI 0.86–
1.40, p = 0.47). Moreover, there were no significant differ-
ences in renal recovery and hospital mortality among both
groups. This trial had several limitations, including dif-
ferent dialysis modes (HD, SLED, CVVHDF) and the
non-report of the members of patients in each group
receiving each type of RRT.
The Randomized Evaluation of Normal versus Aug-
mented Level (RENAL) Replacement Therapy Study is
the largest RCT to date evaluating the dose of CRRT for
AKI [18]. The 1508 participants with AKI requiring RRT
were randomly assigned to post-dilution CVVHDF with
an effluent flow of 40 mL/kg/h (higher intensity therapy:
n = 747) or 25 mL/kg/h (lower intensity therapy: n =
761). This trial also showed that higher intensity therapy
did not lead to improvement in 28- and 90-day mortality
compared with lower intensity therapy. The 90-day mor-
tality in these two groups was 44.7 % (322/721) and
44.7 % (332/743), respectively (OR 1.00, 95 % CI 0.81–
1.23, p = 0.99). These two large multicenter RCTs failed
to show that more intensive RRT improved mortality in
patients with AKI receiving RRT. Prowle et al., in a
current clinical review, suggested that CRRT delivered
dose of <20 mL/kg/h should be avoided, and they recom-
mended 20 to 25 mL/kg/h in patients with AKI requiring
CRRT [19]. Similarly, in Kidney Disease: Improving Global
Outcomes (KDIGO) clinical practice guidelines for acute
kidney injury, delivered dose of 20 to 25 mL/kg/h should
be recommended for optimal dose of CRRT in patients
with AKI [20].
In Japan, however, the standard CRRT dose for patients
with AKI is 600–800 mL/h, equivalent to approximately
10–13 mL/kg/h based on an average weight of Japanese
patients in the ICU of 60 kg, with health insurance paying
for only a very low dose for CRRT. To date, no RCT has
shown that very low doses for CRRT improved survival
and renal recovery compared with standard doses in
patients with AKI. However, two recent retrospective
observational studies assessed whether very low-intensity
CRRT was associated with improved mortality and renal
recovery in patients with AKI [21, 22]. Fujii et al. found no
significant differences in ICU (34 vs 43 %, p = 0.37) and
in-hospital (36 vs 53 %, p = 0.055) mortality between
patients treated with very low-intensity CVVHDF (mean
dose of 14.2 mL/kg/h) and conventional CVVHDF (mean
dose of 20.0 mL/kg/h [21]. In addition, Uchino et al. dem-
onstrated that CRRT with mean intensity of 14.3 mL/kg/h
did not exacerbate ICU and hospital mortality in patients
with severe AKI requiring CRRT compared with CRRT
with mean intensity of 20.4 mL/kg/h [22]. Further well-
designed prospective RCTs are needed to confirm that
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Several recent clinical trials have assessed whether
HVHF improves mortality and recovery of renal function
in patients with septic AKI [23–25]. A systematic review
found that HVHF, defined as a dose of >50 mL/kg/h, did
not clearly improve mortality in patients with septic AKI
[26, 27]. For example, the high volume in intensive care
(IVOIRE) trial, conducted at 18 ICUs in France and
Belgium and the Netherlands, randomized 140 patients
with septic shock requiring RRT to HVHF (70 mL/kg/h)
or standard-volume hemofiltration (SVHF, 35 mL/kg/h)
[25]. HVHF, however, failed to reduce the 28-day mortality
compared with conventional SVHF.
In contrast, few prospective studies have assessed the
dose of IHD. Schiffl et al., in a single-center study,
assigned 160 patients with AKI in an alternating fashion
to receive IHD on daily or on alternate days [28].
Fourteen-day mortality after the last session of IHD was
significantly lower in daily IHD group (28 %) as compared
with alternate day IHD group (46 %, p = 0.01). Extended
dialysis (ED) and SLED are hybrid modalities involving
low dialysate and blood flow rates and prolonged duration
in critically ill patients with AKI. The Hannover Dialysis
Outcomes Study evaluated the relationships between dose
of ED and mortality and renal recovery in patients with
AKI requiring RRT [29]. One hundred fifty-six patients
were randomly assigned to receive standard ED (to
maintain urea levels between 120 and 150 mg/dL) or
intensified ED (to maintain urea levels < 90 mg/dL);
there were no significant differences in 14-day (70.7 vs.
70.4 %, p = 0.97) and 28-day (61.3 vs. 55.6 %, p = 0.47)
survival between standard ED and intensified ED or in
28-day renal recovery among survivors (63.0 vs. 60.0 %,
p = 0.77).
Other than the optimal dose of RRT for patients with
AKI, clinicians who prescribe CRRT in the ICU should
recognize that prescribed and delivered doses may differ.
Several studies have shown that the actual delivered dose
of CRRT is approximately 70–90 % of the prescribed
dose [30, 31]. Claure-Del Granado et al. compared deliv-
ered with prescribed doses in critically ill patients with
AKI treated with CVVHDF based on urea nitrogen con-
centrations in dialysis fluid [30]. This trial found that theTable 2 Standard RRT modality in Japan
CHDF(CRRT)
Blood flow (mL/min) 80~100
Dialysate flow 500~600 mL/h
Replacement flow (mL/h) 200~300
Treatment period (h) 24
RRT renal replacement therapy, CHDF continuous hemodiafiltration, CRRT continuou
renal replacement therapy, SLED sustained low efficiency dialysisprescribed dose overestimated the actual delivered dose
by 23.8 %, suggesting that the delivered dose should be
increased 20 to 25 % to achieve a prescribed dose in pa-
tients with AKI during CRRT. Treatment downtime and
reductions in filter efficacy contribute to the reductions
in delivered compared with prescribed dose of CRRT. The
most common causes of downtime are routine CRRT
circuit change, problems related to vascular access, and
procedures performed outside the ICU including sur-
gery and other diagnostic methods.
RRT modality and RRT mode in patients with AKI
CRRT and IHD are the mainstays of treatment strategy
in patients with AKI requiring RRT in the ICU. RCTs
comparing these two modalities have failed to provide
evidence for the survival benefits of CRRT over IHD
[32–46]. The clinical question “which is the best treatment
strategy for critically ill patients with AKI requiring
RRT ? CRRT or intermittent renal replacement therapy
(IRRT) ?” admits of further discussion. Moreover, the
relative survival advantages of HDF, HF, HD, and peri-
toneal dialysis in critically ill patients with AKI remain
unclear, with few previous RCTs comparing the effects of
continuous hemodiafiltration (CHDF), continuous hemo-
filtration (CHF), and continuous hemodialysis (CHD) on
patient mortality [47]. Newly developed hybrid technol-
ogy, called extended daily dialysis (EDD)/HDF including
sustained low efficiency dialysis (SLED)/HDF, has been
performed in patients with AKI [48, 49]. EDD is generally
defined as extended (approximately 6–10 h) HD or
HDF using a conventional HD machine, blood flow rates
of 100–200 mL/min, and dialysate flow rates of 200–
300 mL/min (Table 2).
A large meta-analysis, performed by the Cochrane
Collaboration, evaluated 15 RCTs involving 1550 patients
with AKI [50]. This analysis showed no significant differ-
ences between patients treated with CRRT and IRRT in
ICU (relative risk (RR) 1.06, 95 % CI 0.90–1.26) and hos-
pital (RR 1.01, 95 % CI 0.92–1.12) mortality and in renal
recovery. The KDIGO clinical practice guidelines for acute
kidney injury in 2012 suggested that CRRT is preferable in
hemodynamically unstable patients with AKI and in pa-
tients with acute brain injury or other causes of increased
intracranial pressure or generalized brain edema [20].IHD (IRRT) SLED
200~250 100~200
500 mL/min 200~300 mL/min
3~5 6~10
s renal replacement therapy, IHD intermittent hemodialysis, IRRT intermittent
Negi et al. Renal Replacement Therapy  (2016) 2:31 Page 5 of 7Furthermore, Surviving Sepsis Campaign Guidelines
(SSCG) also suggested that CRRT and IRRT showed no
differences in short-term mortality in patients with se-
vere sepsis and AKI [51]. A current systematic review
and meta-analysis evaluating 7 RCTs and 16 observational
studies compared the rate of dialysis dependence among
survivors [52]. Evaluation of the RCTs showed no signifi-
cant differences in the rate of dialysis dependence between
IRRT and CRRT (RR 1.15, 95 % CI 0.78–1.68). In con-
trast, observational studies revealed that the relative
risk of IRRT compared with CRRT for dialysis depend-
ence was 1.99 (95 % CI 1.53–2.59). The largest RCT,
which enrolled 360 patients with AKI, showed no dif-
ference in 60-day mortality between the CRRT and
IRRT groups [40]. The most recent RCT, in which 252
patients with AKI were randomized to receive IHD (n =
129) or CVVH (n = 123), found that the univariate ORs for
the IHD group were 1.27 (95 % CI 0.76–2.12, p = 0.36) for
14-day mortality, 1.37 (95 % CI 0.82–2.27, p = 0.22) for 28-
day mortality, and 1.26 (95 % CI 0.76–2.10, p = 0.37) for
intrahospital mortality [46]. In this way, the newest RCT
failed to show that CRRT was superior to IRRT in critically
ill patients with AKI requiring RRT. In addition, a recent
meta-analysis evaluated seven RCTs and ten observational
studies that compared EDD with CRRT in patients with
AKI [53]. Although evaluation of the RCTs revealed no sig-
nificant difference in mortality between EDD and CRRT
(RR 0.90, 95 % CI 0.74–1.11, p = 0.3), the observational
studies showed that the mortality was lower in patients
treated with EDD than CRRT. Further, high-quality RCTs
are required to confirm these results.
Many trials have investigated the impact of the RRT
modality in patients with AKI on mortality and renal re-
covery. In contrast, the standard criteria for RRT mode
(HD, HF, HDF) in AKI patients have not yet been estab-
lished. Moreover, few RCTs have revealed that any RRT
mode results in higher survival than the other modes in
patients with AKI. Wald et al. assigned 78 critically ill
patients with AKI to CVVH group or continuous veno-
venous hemodialysis (CVVHD) group in Optimal Mode
of clearance in critically ill patients with Acute Kidney
Injury (OMAKI) study conducted in Canada [47]. Sixty-
day mortality and dialysis dependence in survivors were
similar between CVVH group and CVVHD group (54
vs.55 % for mortality, 24 vs.19 % for dialysis depend-
ence, respectively). The Beginning and Ending Support-
ive Therapy (BEST) kidney study, analyzing current
methods of CRRT for AKI among 54 ICUs in 23 coun-
tries, showed that CVVHF was used most commonly
(52.8 %), followed by CVVHDF (34 %) and CVVHD
(13.1 %) [54]. In Japan, approximately 80 % of patients
with AKI in the ICU who require CRRT are treated with
CHDF [55]. At present, there is insufficient evidence or
consensus to recommend the best RRT treatmentmodality for patients with AKI requiring RRT, although
CRRT may be preferable to IRRT in hemodynamically
unstable patients with AKI.
Dialysis membranes for RRT in patients with AKI
Various dialysis membranes have been used for IHD
and CRRT in patients with AKI. These membranes have
been classified as biocompatible membranes (BCM) and
bioincompatible membranes (BICM). BCM are made of
synthetic materials including polyacrylonitrile (PAN),
polymethylmethacrylate (PMMA), polyamide (PA), and
polysulfone (PS).
BICM are made of unsubstituted cellulose (cupurophane).
Exposure of blood to the dialysis membranes during RRT
activates complement and cytokines, with BCM being less
active than BICM. Several studies have compared the
impact of these two membrane types on mortality among
patients with AKI. Six RCTs showed no significant differ-
ences in mortality or recovery of renal function between
BCM and BICM [56–61]. Thus, KDIGO clinical practice
guidelines for acute kidney injury have recommended
BCM for IHD and CRRT in patients with AKI [20].
Similarly, a systematic review of seven RCTs comparing
mortality in patients undergoing RRT with BCM and
BICM revealed that the use of unsubstituted cellulose
membranes should be avoided in patients with AKI
[62]. A recent inclusive meta-analysis by the Cochrane
Collaboration, analyzing nine RCTs and quasi-randomized
controlled trials in 1062 patients with AKI requiring IHD,
failed to show that BCM resulted in lower mortality and
higher rates of renal function recovery when compared
with BICM [63].
Conclusions
Despite several advances in the diagnosis and treatment
for AKI, this condition remains associated with unaccept-
ably high morbidity and mortality during the past few de-
cades. In particular, when severe enough to need RRT,
mortality in critically ill patients with AKI is increasing.
Although RRT plays an important role in the treatment of
AKI, the timing of initiation and discontinuation of RRT
has not been established. In addition, previous studies
have failed to show that CRRT is the superior to IRRT in
patients with AKI or significant differences between BCM
and BCIM. Only in terms of optimal dose of RRT for AKI,
two recent RCTs demonstrated that high dose of RRT
does not lead to the improvement of survival rate in pa-
tients with AKI. Further well-designed RCTs are required
to optimize RRT for patients with AKI.
Abbreviations
AKI: acute kidney injury; ATN: Acute Renal Failure Trial Network;
BCM: biocompatible membranes; BEST: Beginning and Ending Supportive
Therapy; BICM: bioincompatible membranes; CHD: continuous hemodialysis;
CHDF: continuous hemodiafiltration; CHF: continuous hemofiltration;
Negi et al. Renal Replacement Therapy  (2016) 2:31 Page 6 of 7CI: confidence interval; CRRT: continuous renal replacement therapy;
CVVH: continuous veno-venous hemofiltration; CVVHD: continuous veno-
venous hemodialysis; CVVHDF: continuous veno-venous hemodiafiltration;
CVVHF: continuous veno-venous hemofiltration; ED: extended dialysis;
EDD: extended daily dialysis; HD: hemodialysis; HDF: hemodiafiltration;
HF: hemofiltration; HVHF: high-volume hemofiltration; ICU: intensive care unit;
IHD: intermittent hemodialysis; IRRT: intermittent renal replacement therapy;
IVOIRE: high volume in intensive care; KDIGO: Kidney Disease: Improving Global
Outcomes; OMAKI: Optional Mode of clearance in critically ill patients with Acute
Kidney Injury; OR: odds ratio; PA: polyamide; PAN: polyacrylonitrile;
PMMA: polymethylmethacrylate; PS: polysulfone; RCT: randomized controlled trial;
RENAL: Randomized Evaluation of Normal versus Augmented Level; RR: relative
risk; RRT: renal replacement therapy; SCr: serum creatinine; SLED: sustained
low-efficiency dialysis; SOFA: Sequential Organ Failure Assessment;
SSCG: Surviving Sepsis Campaign Guidelines; SVHF: standard volume
hemofiltration; vs.: versus.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SN made the substantial contributions to the study conception and design,
and acquisition analysis, and interpretation of the data. DK, SK, YI, and TS
helped to draft the manuscript. All authors read and approved the final
manuscript submitted for publication.
Authors’ information
SN is an associate professor in the Division of Nephrology, Department of
Internal Medicine, Wakayama Medical University. SN, DK, SK, YI, and TS are
physicians specializing in nephrology, blood purification, and renal replacement
therapy in critical care. DK is a section chief in the Division of Blood Purification
Medicine, Kinan Hospital. TS is a director and professor in the Division of
Nephrology, Department of Internal Medicine, Wakayama Medical University.
Acknowledgements
None. No funding to declare.
Author details
1Division of Nephrology, Department of Internal Medicine, Wakayama
Medical University, 811-1 Kimiidera, Wakayama-City, Wakayama-Prefecture
641-8509, Japan. 2Division of Blood Purification Medicine, Kinan Hospital,
Wakayama, Japan.
Received: 18 February 2016 Accepted: 8 April 2016
References
1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al.
Acute renal failure in critically ill patients: a multinational, multicar study.
JAMA. 2005;294:813–18.
2. Mehta RL, Pascaul MT, Soroko S, Savage DR, Himmelfarb J, Ikizler TA, et al.
Spectrum of acute renal failure in the intensive care unit:the PICARD
experience. Kidney Int. 2004;66:1613–21.
3. Tolwani A. Continuous renal-replacement therapy for acute kidney injury.
N Engl J Med. 2012;367:2505–14.
4. Bouman CSC, Oudemans-Van Straaten HM, Tijssen JGP, Zandstra DF,
Zandstra DF, Kesecioglu J. Effccts of early high-volume continuous
venovenous hemofiltration on survival and recovery of renal function in
intensive care patients with acute renal failure: a prospective, randomized
trial. Crit Care Med. 2002;30:2205–11.
5. Sugahara S, Suzuki H. Early start on continuous hemodialysis therapy
improves survival rate in patients with acute renal failure following coronary
bypass surgery. Hemodial Int. 2004;8:320–25.
6. Liu KD, Himmelfarb J, Paganini E, Ikizler TA, Soroko SH, Mehta RL, et al.
Timing of initiation of dialysis in critically ill patients with acute kidney
injury. Clin J Am Soc Nephrol. 2006;1:915–19.
7. Bagshaw SM, Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, et al.
Timing of renal replacement therapy and clinical outcomes in critically ill
patients with severe acute kidney injury. J Crit Care. 2009;24:129–40.8. Shum HP, Chan KC, Kwan MC, Yeung AWT, Cheung EWS, Yan WW. Timing
for initiation of continuous renal replacement therapy in patients with
severe septic shock and acute kidney injury. Ther Apher Dial. 2013;17:305–10.
9. Combes A, Bréchot N, Amour J, Cozic N, Lebreton G, Guidon C, et al. Early
high-volume hemofiltration vs. standard care for postcardiac surgery shock
(the HEROICS study). Am J Respir Crit Care Med. 2015;192:1179–90.
10. Karvellas CJ, Farhat MR, Sajjad I, Mogensen SS, Leung AA, Wald R, et al. A
comparison of early versus late initiation of renal replacement therapy in
critically ill patients with acute kidney injury: a systematic review and
meta-analysis. Crit Care. 2011;15:R72.
11. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al.
Discontinuation of continuous renal replacement therapy: a post hoc analysis of
a prospective multicenter observational study. Crit Care Med. 2009;37:2576–82.
12. Wu VC, Ko WJ, Chang HW, Chen YW, Lin YF, Shiao CC, et al. Risk factors of
early redialysis after weaning from postoperative acute renal replacement
therapy. Intensive Care Med. 2008;34:101–8.
13. Kawarazaki H, Uchino S, Tokuhira N, Ohnuma T, Namba Y, Katayama S, et al.
Who may not benefit from continuous renal replacement therapy in acute
kidney injury. Hemodial Int. 2013;17:624–32.
14. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, et al. Effects
of different doses in continuous veno-venous haemofiltration on outcomes
of acute renal failure: a prospective randomised trial. Lancet. 2000;356:26–30.
15. Saudan P, Niederberger M, De Seigneux S, Romand J, Pugin J, Perneger T,
et al. Adding a dialysis dose to continuous hemofiltration increases survival
in patients with acute renal failure. Kidney Int. 2006;70:1312–7.
16. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM. Standard
versus high-dose CVVHDF for ICU-relate acute renal failure. J Am Soc
Nephrol. 2008;19:1233–8.
17. The VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH,
O′Connor TZ, Chertow GM, Crowley ST, et al. Intensity of renal support in
critically ill patients with acute kidney injury. N Engl J Med. 2008;359:7–20.
18. The RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A,
Cole L, Finfer S, Gallagher M, et al. Intensity of continuous renal-replacement
therapy in critically ill patients. N Engl J Med. 2009;361:1627–38.
19. Prowle JR, Schneider A, Bellomo R. Clinical review: optimal dose of continuous
renal replacement therapy in acute kidney injury. Crit Care. 2011;15:207–14.
20. The Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. KDIGO
Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2:1–138.
21. Fujii T, Namba Y, Fujitani S, Sasaki J, Narihara K, Shibagaki Y, et al. Low-dose
continuous renal replacement therapy for acute kidney injury. Int J Artif
Organs. 2012;35:525–30.
22. Uchino S, Toki N, Takeda K, Ohnuma T, Namba Y, Katayama S, et al. Validity
of low-inensity continuous renal replacement therapy. Crit Care Med.
2013;41:2584–91.
23. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume
haemofiltration in human septic shock. Intensive Care Med. 2001;27:978–86.
24. Reiter K, D′lntini V, Bordoni V, Baldwin I, Bellomo R, Tetta C, et al. High-volume
hemofiltration in sepsis. Nephron. 2002;92:252–58.
25. Joannes-Boyau O, Honoré PM, Perez P, Bagshaw SM, Grand H, Canivet JL,
et al. High-volume versus standard-volume haemofiltration for septic shock
patients with acute kidney injury (IVOIRE study): a multicentre randomized
controlled trial. Intensive Care Med. 2013;39:1535–46.
26. Lehner GF, Wiedermann CJ, Joannidis M. High-volume hemofiltration in
critically ill patients: a systematic review and meta-analysis. Menerva
Anestesiol. 2014;80:595–609.
27. Clark E, Molnar AO, Joannes-Boyau O, Honoré PM, Sikora L, Bagshaw SM.
High-volume hemofiltration for septic acute kidney injury: a systematic
review and meta-analysis. Crit Care. 2014;18:R7.
28. Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute
renal failure. N Engl J Med. 2002;346:305–10.
29. Faulhaber-Walter R, Hafer C, Jahr N, Vablbruch J, Hoy L, Haller H, et al. The
Hannover Dialysis Outcome study: comparison of standard versus
intensified extended dialysis for treatment of patients with acute kidney
injury in the intensive care unit. Nephrol Dial Transplant. 2009;24:2179–86.
30. Claure-Del Granado R, Macedo E, Chertow GM, Soroko S, Himmelfarb J,
Ikizler TA, et al. Effluent volume in continuous renal replacement therapy
overestimates the delivered dose of dialysis. Clin J Am Soc Nephrol.
2011;6:467–75.
31. Vesconi S, Cruz DN, Fumagalli R, Kindgen-Milles D, Monti G, Marinho A, et al.
Deliverde dose of renal replacement therapy and mortality in critically ill
patients with acute kidney injury. Crit Care. 2009;13:R57.
Negi et al. Renal Replacement Therapy  (2016) 2:31 Page 7 of 732. Misset B, Timsit JF, Chevret S, Renaud B, Tamion F, Carlet J. A randomized
cross-over comparison of the hemodynamic response to intermittent
hemodialysis and continuous hemofiltration in ICU patients with acute renal
failure. Intensive Care Med. 1996;22:742–6.
33. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, et al.
A randomized clinical trial of continuous versus intermittent dialysis for
acute renal failure. Kidney Int. 2001;60:1154–63.
34. John S, Griesbach D, Baumgärtel M, Weihprecht H, Schmieder RE, Geiger H.
Effects of continuous haemofiltration vs intermittent haemodialysis on
systemic haemodynamics and splanchnic regional perfusion in septic shock
patients: a prospective, randomized clinical trial. Nephrol Dial Transplant.
2001;16:320–7.
35. Gašparović V, Filipović-Grćić I, Merkler M, Pišl Z. Continuous renal replacement
therapy (CRRT) or intermittent hemodialysis (IHD)- what is the procedure of
choice in critically ill patients? Ren Fail. 2003;25:855–62.
36. Augustine JJ, Sandy D, Seifert TH, Paganini EP. A randomized controlled trial
comparing intermittent with continuous dialysis in patients with ARF. Am J
Kidney Dis. 2004;44:1000–7.
37. Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, et al. Efficacy
and cardiovascular tolerability of extended dialysis in critically ill patients: a
randomized controlled study. Am J Kidney Dis. 2004;43:342–9.
38. Kumar VA, Yeun JY, Depner TA, Don BR. Extended daily dialysis vs. continuous
hemodialysis for ICU patients with acute renal failure: a two-year single center
report. Int J Artif Organs. 2004;27:371–9.
39. Uehlinger DE, Jakob SM, Ferrari P, Eichelberger M, Huynh-Do U, Marti HP,
et al. Comparison of continuous and intermittent renal replacement therapy
for acute renal failure. Nephrol Dial Transplant. 2005;20:1630–7.
40. Vinsonneau C, Camus C, Combes A, de Beauregard MA C, Klouche K,
Boulain T, et al. Continuous venovenous haemodiafiltration versus intermittent
haemodialysis for acute renal failure in patients with multiple-organ dysfunction
syndrome: a multicentre randomised trial. Lancet. 2006;368:379–85.
41. Abe M, Okada K, Suzuki M, Nagura C, Ishihara Y, Fujii Y, et al. Comparison of
sustained hemodiafiltration with continuous venovenous hemodiafiltration
for the treatment of critically ill patients with acute kidney injury. Artif
Organs. 2010;34:331–8.
42. Lins RL, Elseviers MM, Van der Niepen P, Hoste E, Malbrain ML, Damas P,
et al. Intermittent versus continuous renal replacement therapy for acute
kidney injury patients admitted to the intensive care unit: results of a
randomized clinical trial. Nephrol Dial Transplant. 2009;24:512–8.
43. Baldwin I, Bellomo R, Naka T, Koch B, Fealy N. A pilot randomized controlled
comparison of extended daily dialysis with filtration and continuous
veno-venous hemofiltration: fluid removal and hemodynamics. Int J Artif
Organs. 2007;30:1083–9.
44. Abe M, Maruyama N, Matsumoto S, Okada K, Fujita T, Matsumoto K, et al.
Comparison of sustained hemodiafiltration with acetate-free dialysate and
continuous venovenous hemodiafiltration for the treatment of critically ill
patients with acute kidney injury. Int J Nephrol. 2011;2011:432094.
45. Schwenger V, Weigand MA, Hoffmann O, Dikow R, Kihm LP, Seckinger J, et al.
Sustained low efficiency dialysis using a single-pass batch system in acute
kidney injury—a randomized interventional trial: the REnal Replacement
Therapy Study in Intensive Care Unit PatiEnts. Crit Care. 2012;16:R 140.
46. Schefold JC, von Haehling S, Pschowski R, Bender T, Berkmann C, Briegel S,
et al. The effect of continuous versus intermittent renal replacement
therapy on the outcome of critically ill patients with acute renal failure
(CONVINT): a prospective randomized controlled trial. Crit Care. 2014;18:R11.
47. Wald R, Friedrich JO, Bagshwaw SM, Burns KE, Garg AX, Hladunewich MA,
et al. Optimal mode of clearance in critically ill patients with acute kidney
injury (OMAKI)-a pilot randomized controlled trial of hemofiltration versus
hemodialysis: a Canadian Critical Trial Group project. Crit Care. 2012;16:R205.
48. Kumar VA, Craig M, Depner TA, Yeun YY. Extended daily dialysis: a new
approach to renal replacement for acute renal failure in the intensive care
unit. Am J Kidney Dis. 2000;36:294–300.
49. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK. Sustained
low-efficiency dialysis for critically ill patients requiring renal replacement
therapy. Kidney Int. 2001;60:777–85.
50. Rabindranath KS, Adams J, MacLeod AM, Muirhead N. Intermittent versus
continuous renal replacement therapy for acute renal failure in adults.
Cochrane Database Syst Rev 2007;3:CD003773.
51. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.
Surviving sepsis campaign: international guidelines for management of
severe sepsis and septic shock:2012. Crit Care Med. 2013;41:580–637.52. Schneider AG, Bellomo R, Bagshaw SM, Glassford NJ, Lo S, Jun M, et al.
Choice of renal replacement therapy modality and dialysis dependence
after acute kidney injury: a systematic review and meta-analysis. Intensive
Care Med. 2013;39:987–97.
53. Zhang L, Yang J, Eastwood GM, Zhu G, Tanaka A, Bellomo R. Extended daily
dialysis versus continuous renal replacement therapy for acute kidney injury:
a meta-analysis. Am J Kidney Dis. 2015;66:322–30.
54. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al.
Continuous renal replacement therapy: a worldwide practice survey. The
Beginning and Ending Supportive Therapy for the Kidney (B.E.S.T. Kidney)
Investigators. Intensive Care Med. 2007;33:1563–70.
55. Kaizu K, Inada Y, Kawamura A, Oda S, Hirasawa H. Current status of blood
purification in critical care in Japan. Contrib Nephrol. 2010;166:4–10.
56. Schiffl H, Lang SM, König A, Strasser T, Haider MC, Held E. Biocompatible
membranes in acute renal failure: prospective case-controlled study. Lancet.
1994;344:570–2.
57. Jones CH, Goutcher E, Newstead CG, Will EJ, Dean SG, Davison AM.
Hemodynamics and survival of patients with acute renal failure treated by
continuous dialysis with two synthetic membranes. Artif Organs. 1998;22:638–43.
58. Jörres A, Gahl GM, Dobis C, Polenakovic MH, Cakalaroski K, Rutkowski B, et al.
Haemodialysis-membrane biocompatibility and mortality of patients with
dialysis-dependent acute renal failure: a prospective randomised multicentre
trial. Lancet. 1999;354:1337–41.
59. Gastaldello K, Melot C, Kahn RJ, Vanherweghem JL, Vincent JL, Tielemans C.
Comparison of cellulose diacetate and polysulfone membranes in the
outcome of acute renal failure. A prospective randomized study. Nephrol
Dial Transplant. 2000;15:224–30.
60. Albright Jr RC, Smelser JM, McCarthy JT, Homburger HA, Bergstralh EJ,
Larson TS. Patient survival and renal recovery in acute renal failure:
randomized comparison of cellulose acetate and polysulfone membrane
dialyzers. Mayo Clin Proc. 2000;75:1141–7.
61. Ponikvar JB, Rus RR, Kenda RB, Bren AF, Ponikvar RR. Low-flux versus high-flux
synthetic dialysis membrane in acute renal failure: prospective randomized
study. Artif Organs. 2001;25:946–50.
62. Pannu N, Klarenbach S, Wiebe N, Manns B, Tonelli M. Alberta Kidney Disease
Network. Renal replacement therapy in patients with acute renal failure. JAMA.
2008;299:793–805.
63. Alonso A, Lau J, Jaber BL. Biocompatible hemodialysis membranes for acute
renal failure. Cochrane Database Syst Rev. 2008;1:CD005283.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
